{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:31:06Z","timestamp":1794486666406,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":43,"publisher":"Springer New York","isbn-type":[{"value":"9781493915378","type":"print"},{"value":"9781493915385","type":"electronic"}],"license":[{"start":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T00:00:00Z","timestamp":1411430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T00:00:00Z","timestamp":1411430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-1-4939-1538-5_17","type":"book-chapter","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T02:14:49Z","timestamp":1413339289000},"page":"277-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting bcr-abl Transcripts with siRNAs in an Imatinib-Resistant Chronic Myeloid Leukemia Patient: Challenges and Future Directions"],"prefix":"10.1007","author":[{"given":"Michael","family":"Koldehoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,23]]},"reference":[{"key":"17_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldmann","year":"2003","unstructured":"Goldmann JM, Melo JV (2003) Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment. N Engl J Med 349:1451\u20131461","journal-title":"N Engl J Med"},{"key":"17_CR2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"17_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/j.1432-0436.2008.00270.x","volume":"76","author":"M Simanovsky","year":"2008","unstructured":"Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, Galski H (2008) Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia. Differentiation 76:908\u2013922","journal-title":"Differentiation"},{"key":"17_CR4","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M et al (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103:2794\u20132799","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14796694.1.1.103","volume":"1","author":"H Lage","year":"2005","unstructured":"Lage H (2005) Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 1:103\u2013113","journal-title":"Future Oncol"},{"key":"17_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494\u2013498","journal-title":"Nature"},{"key":"17_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806\u2013811","journal-title":"Nature"},{"key":"17_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","volume":"19","author":"JC Burnett","year":"2012","unstructured":"Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60\u201371","journal-title":"Chem Biol"},{"key":"17_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrg1323","volume":"5","author":"V Mittal","year":"2004","unstructured":"Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nat Rev Genet 5:355\u2013365","journal-title":"Nat Rev Genet"},{"key":"17_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12:967\u2013977","journal-title":"Nat Mater"},{"key":"17_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0092-8674(03)00759-1","volume":"115","author":"DS Schwarz","year":"2003","unstructured":"Schwarz DS, Hutv\u00e1gner G, Du T, Xu Z, Aronin N, Zamore PD (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199\u2013208","journal-title":"Cell"},{"key":"17_CR12","first-page":"326","volume":"90","author":"AH Elmaagacli","year":"2005","unstructured":"Elmaagacli AH, Koldehoff M, Peceny R et al (2005) WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90:326\u2013334","journal-title":"Haematologica"},{"key":"17_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2009.016063","volume":"95","author":"M Koldehoff","year":"2010","unstructured":"Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH (2010) Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 95:388\u2013397","journal-title":"Haematologica"},{"key":"17_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/cgt.2013.31","volume":"20","author":"M Koldehoff","year":"2013","unstructured":"Koldehoff M, Zakrzewski JL, Beelen DW, Elmaagacli AH (2013) Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Ther 20:421\u2013427","journal-title":"Cancer Gene Ther"},{"key":"17_CR15","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1182\/blood-2002-03-0675","volume":"100","author":"A Gratwohl","year":"2002","unstructured":"Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A (2002) Current trends in hematopoietic stem cell transplantation in Europe. Blood 100:2374\u20132386","journal-title":"Blood"},{"key":"17_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1\u20137","journal-title":"Leuk Lymphoma"},{"key":"17_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00109-004-0558-8","volume":"82","author":"CR Dass","year":"2004","unstructured":"Dass CR (2004) Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med 82:579\u2013591","journal-title":"J Mol Med"},{"key":"17_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.addr.2003.10.037","volume":"56","author":"E Fattal","year":"2004","unstructured":"Fattal E, Couvreur P, Dubernet C (2004) \u201cSmart\u201d delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Del Rev 56:931\u2013946","journal-title":"Adv Drug Del Rev"},{"key":"17_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10238-007-0125-z","volume":"7","author":"M Koldehoff","year":"2007","unstructured":"Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH (2007) Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7:47\u201355","journal-title":"Clin Exp Med"},{"key":"17_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrd2310","volume":"6","author":"A de Fougerolles","year":"2007","unstructured":"de Fougerolles A, Vornlocher HP, Maraganore J, Liebermann J (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443\u2013453","journal-title":"Nat Rev Drug Discov"},{"key":"17_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2133\/dmpk.22.142","volume":"22","author":"S Kawakami","year":"2007","unstructured":"Kawakami S, Hashida M (2007) Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 22:142\u2013151","journal-title":"Drug Metab Pharmacokinet"},{"key":"17_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nature03121","volume":"432","author":"J Soutschek","year":"2004","unstructured":"Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173\u2013178","journal-title":"Nature"},{"key":"17_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nbt1122","volume":"23","author":"DV Morrissey","year":"2005","unstructured":"Morrissey DV, Lockridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002\u20131007","journal-title":"Nat Biotechnol"},{"issue":"7","key":"17_CR24","first-page":"09","volume":"23","author":"E Song","year":"2005","unstructured":"Song E, Zhu P, Lee S-K et al (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23(7):09\u2013717","journal-title":"Nat Biotechnol"},{"key":"17_CR25","first-page":"1","volume":"1","author":"H Sezaki","year":"1984","unstructured":"Sezaki H, Hashida M (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. Crit Rev Ther Drug Carrier Syst 1:1\u201338","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"17_CR26","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","volume":"101","author":"M Scherr","year":"2003","unstructured":"Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M (2003) Specific inhibition of BCR-ABL gene expression by small interfering RNA. Blood 101:1566\u20131569","journal-title":"Blood"},{"key":"17_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1124\/jpet.102.036749","volume":"303","author":"KL Sewell","year":"2002","unstructured":"Sewell KL, Geary RS, Baker BF et al (2002) Phase I trial of ISIS 104838, a 2\u2032-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-\u03b1. J Pharmacol Exp Ther 303:1334","journal-title":"J Pharmacol Exp Ther"},{"key":"17_CR28","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","volume":"23","author":"SM O\u2019Brian","year":"2005","unstructured":"O\u2019Brian SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR (2005) Phase I and II multicenter study of oblimersen sodium a Bcl-2 antisense oligonucleotide in patients with advanced chronic lymphocytic leukaemia. J Clin Oncol 23:7697\u20137702","journal-title":"J Clin Oncol"},{"key":"17_CR29","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1093\/nar\/gkg649","volume":"31","author":"R Kretschmer-Kazemi Far","year":"2003","unstructured":"Kretschmer-Kazemi Far R, Sczakiel G (2003) The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 31:4417\u20134424","journal-title":"Nucleic Acids Res"},{"key":"17_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cncr.11909","volume":"100","author":"R Advani","year":"2004","unstructured":"Advani R, Peethambaram P, Lum BL et al (2004) A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with ovarian carcinoma. Cancer 100:321\u2013326","journal-title":"Cancer"},{"key":"17_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1182\/blood-2002-06-1899","volume":"101","author":"G Marcucci","year":"2003","unstructured":"Marcucci G, Byrd JC, Dai G et al (2003) Phase 1 and pharmacodynamic studies of G3139, a BCL-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed leukemia. Blood 101:425\u2013432","journal-title":"Blood"},{"key":"17_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/01.moh.0000148551.93303.9e","volume":"12","author":"J Goldman","year":"2004","unstructured":"Goldman J (2004) Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukaemia in the imatinib era. Curr Opin Hematol 12:33\u201339","journal-title":"Curr Opin Hematol"},{"key":"17_CR33","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S et al (2002) High frequency of point mutation clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukaemia or Ph-positive acute lymphoblastic leukaemia who develop imatinib (STI571) resistance. Blood 99:3472\u20133475","journal-title":"Blood"},{"key":"17_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsch S et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276\u2013283","journal-title":"Blood"},{"key":"17_CR35","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","volume":"102","author":"L Wohlbold","year":"2003","unstructured":"Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE (2003) Inhibition of BCR-ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102:2236\u20132269","journal-title":"Blood"},{"key":"17_CR36","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","volume":"21","author":"M Wilda","year":"2002","unstructured":"Wilda M, Fuchs U, W\u00f6ssmann W, Borkhardt A (2002) Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference. Oncogene 21:5716\u20135724","journal-title":"Oncogene"},{"key":"17_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2141.2005.05468.x","volume":"129","author":"JM Withey","year":"2005","unstructured":"Withey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR, Gordon MY (2005) Targeting primary human leukaemia cells with RNA interference: BCR-ABL targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol 129:377\u2013380","journal-title":"Br J Haematol"},{"key":"17_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1023\/A:1010338219401","volume":"20","author":"W Guo","year":"2000","unstructured":"Guo W, Lee RJ (2000) Efficient gene delivery using anionic liposome-complexed polyplexes (LPDII). Biosci Rep 20:419\u2013432","journal-title":"Biosci Rep"},{"key":"17_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbamem.2005.03.004","volume":"1711","author":"SD Patil","year":"2005","unstructured":"Patil SD, Rhodes DG, Burgess DJ (2005) Biophysical characterization of anionic lipoplexes. Biochim Biophys Acta 1711:1\u201311","journal-title":"Biochim Biophys Acta"},{"key":"17_CR40","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1:347\u2013355","journal-title":"Mol Cancer Ther"},{"key":"17_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm1191","volume":"11","author":"V Hornung","year":"2005","unstructured":"Hornung V, Guenthner-Biller M, Bourquin C et al (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263\u2013270","journal-title":"Nat Med"},{"key":"17_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00253-007-0984-y","volume":"76","author":"A Aigner","year":"2007","unstructured":"Aigner A (2007) Application of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76:9\u201321","journal-title":"Appl Microbiol Biotechnol"},{"key":"17_CR43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00439-013-1288-1","volume":"132","author":"T Mart\u00ednez","year":"2013","unstructured":"Mart\u00ednez T, Wright N, L\u00f3pez-Fraga M, Jim\u00e9nez AI, Pa\u00f1eda C (2013) Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet 132:481\u2013493","journal-title":"Hum Genet"}],"container-title":["Methods in Molecular Biology","RNA Interference"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-1538-5_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T22:14:03Z","timestamp":1674252843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-4939-1538-5_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,23]]},"ISBN":["9781493915378","9781493915385"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-1538-5_17","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-1538-5","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,23]]},"assertion":[{"value":"23 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}